AKT1 and breast carcinoma: The exception is the AKT/ERK1/2/STAT3 pathway, which is affected by CD36 silencing or blocking in breast cancer (Sp et al., 2018; Gyamfi et al., 2021), HCC (Luo et al., 2021), leukemia (Zhang et al., 2020), GBM (Hale et al., 2014), cervical cancer (Yang et al., 2018), and CRC (Park et al., 2019).